New drug combo trial targets advanced cancers with specific mutation
NCT ID NCT06520488
Summary
This early-stage trial is testing whether a new drug called HRS-4642, when combined with other cancer treatments, is safe and effective for people with advanced solid tumors that have a specific genetic change (KRAS G12D mutation). The study aims to find the best dose and see if the combination helps shrink tumors. It will enroll about 118 adults whose cancer has progressed despite standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200127, China
Contact
Conditions
Explore the condition pages connected to this study.